AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18294337 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength CQ + SDx/PYR combination
Number of subjects: 86
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mydriatic photography
Number of subjects: 3650
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriatic photography
Number of subjects: 3650
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of obvious central cataract
Number of subjects: 3650
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of early cataract
Number of subjects: 3650
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: No cataract
Number of subjects: 3650
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Other pathologies
Number of subjects: 3650
Study 16186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil diameter
Number of subjects: 3650
Study 14608559 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol and acupressure bands
Number of subjects: 143
Study 14608559 — intervention group
Group type: COMPARATOR
Intervention: Droperidol and placebo bands
Number of subjects: 143
Study 14608559 — intervention group
Group type: COMPARATOR
Intervention: Placebo drug and acupressure bands
Number of subjects: 143
Study 14608559 — intervention group
Group type: COMPARATOR
Intervention: Placebo drug and placebo bands
Number of subjects: 143
Study 10513645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir, zidovudine, and lamivudine
Number of subjects: 0
Study 7745195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice applied to subcutaneous heparin injection sites
Number of subjects: 70
Study 2174657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 16
Study 2174657 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallidin
Number of subjects: 16
Study 2174657 — intervention group
Group type: EXPERIMENTAL
Intervention: [des-Arg9]bradykinin
Number of subjects: 16
Study 2174657 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 16
Study 7114515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (therapy group)
Number of subjects: 40
Study 7114515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (therapy group)
Number of subjects: 40
Study 7114515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (preventive group)
Number of subjects: 40
Study 7114515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (preventive group)
Number of subjects: 40
Study 29461414 — intervention group
Group type: EXPERIMENTAL
Intervention: On-court fitness test (ST)
Number of subjects: 8
Study 28844621 — intervention group
Group type: EXPERIMENTAL
Intervention: Unedited risk statement
Number of subjects: 1500
Study 28844621 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious and actionable risks only
Number of subjects: 1500
Study 28844621 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure indicating that not all risks are presented
Number of subjects: 1500
Study 28844621 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1500
Study 26814004 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational intervention (booklet, individual teaching session, follow-up support call)
Number of subjects: 143
Study 26814004 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual teaching)
Number of subjects: 143
Study 26814004 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational intervention
Number of subjects: 143
Study 26814004 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 143
Study 25332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy diet (3 servings/d: 375 mL low-fat milk, 175 g low-fat yogurt, 30 g regular-fat cheddar cheese)
Number of subjects: 112
Study 25332474 — intervention group
Group type: COMPARATOR
Intervention: Control diet (energy-matched: fruit juice, vegetable juice, cashews, and 1 cookie)
Number of subjects: 112
Study 25332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy diet
Number of subjects: 112
Study 25332474 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 112
Study 23053790 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone (ng/mL)
Number of subjects: 898
Study 23053790 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG (nmol/L)
Number of subjects: 898
Study 23053790 — intervention group
Group type: EXPERIMENTAL
Intervention: Free estradiol (fg/mL)
Number of subjects: 898
Study 20173425 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed form of constraint‐induced therapy
Number of subjects: 13
Study 20173425 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 13
Study 18809812 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet (control group)
Number of subjects: 46
Study 18809812 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% CR from baseline energy requirements (CR group)
Number of subjects: 46
Study 18809812 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% energy deficit by a combination of CR and increased aerobic exercise (CR + EX group)
Number of subjects: 46
Study 18809812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD group)
Number of subjects: 46
Study 16162401 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg)
Number of subjects: 31
Study 16162401 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2-40 mg)
Number of subjects: 31
Study 16162401 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study 16162401 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 31
Study 12389342 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural remedy ('Chick‐Chack') containing coconut oil, anise oil, and ylang ylang oil; applied three times at 5-day intervals for 15 minutes each time.
Number of subjects: 119
Study 12389342 — intervention group
Group type: COMPARATOR
Intervention: Control pediculicide spray containing permethrin, malathion, piperonyl butoxide, isododecane, and propellant gas; applied twice for 10 minutes with a 10-day interval between applications.
Number of subjects: 119
Study 10465324 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-oriented lifestyle modification intervention (home visits, health curricula, group sessions)
Number of subjects: 1740
Study 10465324 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only written information on individual risk profile
Number of subjects: 1740
Study 7605863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once a day for 2 weeks (Group 1)
Number of subjects: 66
Study 7605863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once a day for 4 weeks (Group 2)
Number of subjects: 66
Study 7605863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice a day for 2 weeks (Group 3)
Number of subjects: 66
Study 7605863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice a day for 4 weeks (Group 4)
Number of subjects: 66
Study 2194694 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy combined with ticlopidine 250 mg b.i.d. (group C + T)
Number of subjects: 652
Study 26517 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mequitazine twice daily
Number of subjects: 40
Study 26517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6983839 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg disoprofol
Number of subjects: 10
Study 6983839 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg disoprofol
Number of subjects: 10
Study 6983839 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg thiopentone
Number of subjects: 10
Study 6983839 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/kg thiopentone
Number of subjects: 10
Study 6983839 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg methohexitone
Number of subjects: 10
Study 28683577 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying a support person
Number of subjects: 0
Study 28683577 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying multiple support persons
Number of subjects: 0
Study 28683577 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of social network
Number of subjects: 0
Study 26459570 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech Osseospeed (S1)
Number of subjects: 64
Study 26459570 — intervention group
Group type: EXPERIMENTAL
Intervention: Straumann Bone Level (S2)
Number of subjects: 64
Study 25315167 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum support film
Number of subjects: 552
Study 25315167 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum support film with hotline service
Number of subjects: 552
Study 25315167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotline service alone
Number of subjects: 552
Study 25315167 — intervention group
Group type: COMPARATOR
Intervention: Music CD (control)
Number of subjects: 552
Study 22305678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax (23-valent pneumococcal polysaccharide vaccine)
Number of subjects: 0
Study 20819223 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy (manipulation and mobilization) in addition to usual medical care (UMC)
Number of subjects: 150
Study 20819223 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 150
Study 20819223 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy (manipulation and mobilization)
Number of subjects: 150
Study 17321820 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststroke shoulder pain measured with BPI question 23 (11-point NRS)
Number of subjects: 61
Study 17321820 — intervention group
Group type: COMPARATOR
Intervention: Motor impairment measured with Fugl‐Meyer Assessment (FMA)
Number of subjects: 61
Study 17321820 — intervention group
Group type: COMPARATOR
Intervention: Activity limitation measured with Arm Motor Ability Test (AMAT)
Number of subjects: 61
Study 17321820 — intervention group
Group type: COMPARATOR
Intervention: Activity limitation measured with FIM instrument
Number of subjects: 61
Study 16222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated thermal stimuli on the same side for five daily sessions (Study 1)
Number of subjects: 22
Study 16222074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimuli restricted to one side for four daily sessions, then applied to the other side on the fifth session (Study 2)
Number of subjects: 22
Study 14566490 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen tube (DLT)
Number of subjects: 125
Study 14566490 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen tube (SLT) with intrathoracic CO2 insufflation at a rate of 0.5-1 l.min(-1) and sustained intrathoracic pressure at 6 mmHg
Number of subjects: 125
Study 10101653 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided intratumoral gene therapy (10 ml of a vector solution with replication-defective adenovirus containing wild-type p53 cDNA)
Number of subjects: 6
Study 10101653 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided intratumoral gene therapy (2 ml aliquots injected into different tumor areas)
Number of subjects: 6
Study 10101653 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided intratumoral gene therapy
Number of subjects: 6
Study 7798494 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 2346975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarivid
Number of subjects: 40
Study 2346975 — intervention group
Group type: COMPARATOR
Intervention: Ciproxine
Number of subjects: 40
Study 2346975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarivid and Ciproxine
Number of subjects: 40
Study 224958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate or oral fluphenazine
Number of subjects: 36
Study 224958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 10 mg
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 50 mg
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 150 mg
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 450 mg
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 900 mg
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 3 mg q.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 10 mg q.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 30 mg q.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 100 mg q.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 15 mg b.i.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 30 mg b.i.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 30 mg t.i.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 60 mg b.i.d.
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Escalating b.i.d. dose (30-90 mg total daily)
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor 30 mg b.i.d. with psyllium
Number of subjects: 23
Study 29363027 — intervention group
Group type: COMPARATOR
Intervention: Tenapanor
Number of subjects: 23
Study 27275351 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg doxycycline once daily for 30 days
Number of subjects: 60
Study 27275351 — intervention group
Group type: COMPARATOR
Intervention: 20 mg doxycycline twice daily for 75 days
Number of subjects: 60
Study 25642764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, thalidomide, and dexamethasone (VTD)
Number of subjects: 0
Study 25642764 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide and dexamethasone (TD)
Number of subjects: 0
Study 22972592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 20737820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash lottery incentive ($500 grand prize and five $100 prizes)
Number of subjects: 1150
Study 20737820 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 1150
Study 20737820 — intervention group
Group type: COMPARATOR
Intervention: Online newsletter advertisement (without incentive)
Number of subjects: 1150
Study 18230350 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MT1-MMP levels
Number of subjects: 206
Study 18230350 — intervention group
Group type: COMPARATOR
Intervention: Alendronate therapy
Number of subjects: 206
Study 16641904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (docetaxel 20 mg m(‐2) once weekly every 6 weeks + radiotherapy 2 Gy for 5 days a week, total 60 Gy)
Number of subjects: 108
Study 16641904 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (2 Gy for 5 days a week, total 60 Gy)
Number of subjects: 108
Study 12695290 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 86
Study 12695290 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (beta-blockers)
Number of subjects: 86
Study 11063789 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP (0.5 mg/kg)
Number of subjects: 30
Study 11063789 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 30
Study 9176177 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise training (ANT)
Number of subjects: 0
Study 9176177 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training (AET)
Number of subjects: 0
Study 8449552 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroethylene anaesthesia
Number of subjects: 10
Study 8449552 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia (Control)
Number of subjects: 10
Study 3530933 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V
Number of subjects: 19
Study 3530933 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg E2V
Number of subjects: 19
Study 29357918 — intervention group
Group type: EXPERIMENTAL
Intervention: MUMentum Pregnancy (study 1)
Number of subjects: 50
Study 29357918 — intervention group
Group type: EXPERIMENTAL
Intervention: MUMentum Postnatal (study 2)
Number of subjects: 50
Study 29357918 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 50
Study 27717766 — intervention group
Group type: COMPARATOR
Intervention: Cash incentives
Number of subjects: 800
Study 27717766 — intervention group
Group type: COMPARATOR
Intervention: Charity incentives
Number of subjects: 800
Study 27717766 — intervention group
Group type: COMPARATOR
Intervention: Fitbit tracker
Number of subjects: 800
Study 27717766 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (no tracker or incentives)
Number of subjects: 800
Study 24710666 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent reading of syllables (Experiment 1)
Number of subjects: 0
Study 24710666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing syllables (Experiment 2)
Number of subjects: 0
Study 24710666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitched vocalization
Number of subjects: 0
Study 24710666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pitched vocalization
Number of subjects: 0
Study 23268187 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 hours of perioperative antimicrobial therapy
Number of subjects: 92
Study 23268187 — intervention group
Group type: COMPARATOR
Intervention: 120 hours of perioperative antimicrobial therapy
Number of subjects: 92
Study 20427311 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience response didactic
Number of subjects: 438
Study 20427311 — intervention group
Group type: EXPERIMENTAL
Intervention: Role play
Number of subjects: 438
Study 20427311 — intervention group
Group type: EXPERIMENTAL
Intervention: Human patient simulation
Number of subjects: 438
Study 20427311 — intervention group
Group type: COMPARATOR
Intervention: Didactic (control)
Number of subjects: 438
Study 18617385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric ropivacaine 15 mg
Number of subjects: 80
Study 18617385 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 10 mg with sufentanil 5 micrograms
Number of subjects: 80
Study 15723736 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HG)
Number of subjects: 50
Study 15723736 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective global assessment (SGA)
Number of subjects: 50
Study 15723736 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nutritional index (PNI)
Number of subjects: 50
Study 15723736 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertension and functional gastrointestinal disorders)
Number of subjects: 50
Study 12559446 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch reconstruction
Number of subjects: 50
Study 12559446 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction without pouch
Number of subjects: 50
Study 10891645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.7 g of ethanol/kg body weight)
Number of subjects: 0
Study 9029249 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide imaging (RI)
Number of subjects: 11
Study 9029249 — intervention group
Group type: COMPARATOR
Intervention: Alkaline rinses
Number of subjects: 11
Study 9029249 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 11
Study 1628013 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 40
Study 1628013 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric feeding
Number of subjects: 40
Study 6707381 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.64 mg/kg amrinone
Number of subjects: 17
Study 6707381 — intervention group
Group type: EXPERIMENTAL
Intervention: amrinone therapy
Number of subjects: 17
Study 6707381 — intervention group
Group type: COMPARATOR
Intervention: placebo therapy
Number of subjects: 17
Study 6707381 — intervention group
Group type: EXPERIMENTAL
Intervention: amrinone re-administration
Number of subjects: 17
Study 30838534 — intervention group
Group type: EXPERIMENTAL
Intervention: Video teaching on obesity
Number of subjects: 949
Study 30838534 — intervention group
Group type: COMPARATOR
Intervention: Control (no video teaching)
Number of subjects: 949
Study 28669241 — intervention group
Group type: COMPARATOR
Intervention: Minimal level of intervention components
Number of subjects: 256
Study 28669241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense level of intervention components
Number of subjects: 256
Study 27080598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 100
Study 27080598 — intervention group
Group type: COMPARATOR
Intervention: Traditional hydrophilic primer (Ortho-Solo®)
Number of subjects: 100
Study 24946629 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (electroacupuncture, moxibustion, moving cupping)
Number of subjects: 90
Study 24946629 — intervention group
Group type: COMPARATOR
Intervention: Western medication (vitamin B1 and mecobalamine)
Number of subjects: 90
Study 22215073 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE) with doxorubicin (75, 50, and 25 mg/m² based on bilirubin levels) and lipiodol, combined with continuous sorafenib 800 mg/day
Number of subjects: 15
Study 22215073 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 20807874 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with type 1 diabetes (ADM)
Number of subjects: 51
Study 20807874 — intervention group
Group type: COMPARATOR
Intervention: Subjects with type 1 diabetes
Number of subjects: 51
Study 17392295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizer plus adjunctive antidepressant therapy
Number of subjects: 366
Study 17392295 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilizer plus matching placebo
Number of subjects: 366